Glioma Panel – Advance
Also known as glioma panel – advance glioma panel – advance
-
Home Collection, Lab Visit
- Reports within10 Working Days
Glioma Panel – Advance Package in Jamshedpur Overview
What is Glioma Panel – Advance (EGFR & 1P AND 19Q) test?
A combined assay that evaluates EGFR (commonly amplification and selected mutations/variant III) and detects 1p/19q whole‑arm codeletion, reported within an integrated neuro‑oncology workup. Results help establish lineage: 1p/19q codeletion supports oligodendroglioma when paired with IDH mutation. EGFR amplification is a hallmark feature of IDH‑wildtype glioblastoma and is generally mutually exclusive with true whole‑arm 1p/19q codeletion.
Why consider Glioma Panel – Advance (EGFR & 1P AND 19Q) test?
- Improves diagnostic confidence when histology is limited or equivocal by capturing two pivotal copy‑number signatures that steer classification and grade assignment.
- Guides treatment decisions: EGFR amplification may inform eligibility for EGFR‑targeted strategies/clinical trials, whereas confirmed 1p/19q codeletion predicts chemosensitivity and better outcomes in oligodendroglioma.
Who should get tested for Glioma Panel – Advance (EGFR & 1P AND 19Q) test?
- Patients with newly diagnosed diffuse gliomas in whom distinguishing oligodendroglial lineage from IDH‑wildtype glioblastoma would change management.
- Cases with small biopsies or conflicting findings where EGFR status and 1p/19q copy‑number clarify diagnosis and prognosis, or recurrent disease where re‑profiling may open targeted trial options.
More Information about Glioma Panel – Advance (EGFR & 1P AND 19Q) test
OTHER NAMES: Advanced Glioma Copy‑Number Panel (EGFR + 1p/19q), EGFR amplification with 1p/19q assessment (FISH/NGS), Glioma Advanced Marker Panel (EGFR and 1p/19q)
Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.
No preparations needed
Glioma Panel – Advance parameters Includes: 30
Glioma Panel – Advance
₹31000
WhatsApp to book test
+91 91115-91115


